Current Research Studies

DAY101-EAP, Expanded Access to the Oral Pan-RAF Inhibitor DAY101 in Pediatric Patients with RAF-Altered, Relapsed or Refractory Low-Grade Glioma


What is the goal of the study?

To learn more about this study, please email the study team member listed below.

Who can participate in the study?

Please contact the study team listed below to learn more.

Study Team: